Chemocentryx (CCXI) Awarded $500K FDA Grant

October 17, 2016 1:00 PM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Chemocentryx, Inc. (NASDAQ: CCXI) receives a $500,000 annual grant from the FDA: Petrus Bekker, Phase 2 Study of CCX168 for the Treatment of Anti-Neutrophil Cytoplasmic Auto-Antibodies Associated Vasculitis.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, FDA, Trader Talk

Add Your Comment